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Abstract 
Cisplatin, doxorubicin and fluorouracil (5-FU), drugs belonging to different chemical classes, 
have been extensively used for chemotherapy of various cancers. Despite extensive investi-
gations into their hepatotoxicity, there is very limited information on their effects on the 
structure and ultra-structure of liver cells in vivo. Here, we demonstrate for the first time, 
the effects of these three anticancer drugs on rat liver toxicity using both light and electron 
microscopy.  Light microscopic observations revealed that higher doses of cisplatin and 
doxorubicin caused massive hepatotoxicity compared to 5-FU treatment, including dissolu-
tion of hepatic cords, focal inflammation and necrotic tissues. Interestingly, low doses also 
exhibited abnormal changes, including periportal fibrosis, degeneration of hepatic cords 
and increased apoptosis. These changes were confirmed at ultrastructural level, including 
vesiculated rough endoplasmic reticulum and atrophied mitochondria with ill-differentiated 
cisternae, dense collection of macrophages and lymphocytes as well as fibrocytes with col-
lagenous fibrils manifesting early sign of fibrosis, especially in response to cisplatin and 
doxorubicin -treatment. Our results provide in vivo evidence, at ultrastructural level, of di-
rect hepatotoxicity caused by cisplatin, doxorubicin and 5-FU at both light and electron mi-
croscopi. These results can guide the design of appropriate treatment regimen to reduce the 
hepatotoxic effects of these anticancer drugs. 
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Introduction 
Chemotherapy  involves the use of chemical 
agents to stop the growth and eliminate cancer cells 
even at distant sites from the origin of primary tumor. 
However, it does not distinguish between a cancer 
and normal cells, and eliminates not only the 
fast-growing cancer cells but also other fast-growing 
cells in the body, including, hair and blood cells. More 
than half of all people diagnosed with cancer receive 
chemotherapy regimen, that usually include drugs to 
treat cancer as well as drugs to help support the com-
pletion of the cancer treatment at the full dose on 
schedule (1, 2).   Int. J. Biol. Sci. 2009, 5 
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Cisplatin, doxorubicin and 5-FU have been ex-
tensively used for chemotherapy of various cancers, 
including that of the liver (3-5). However, while they 
generate acceptable outcome in chemotherapy of 
some cancers, they also exhibit severe toxicity and 
undesirable side effects (6-8). Extensive investigations 
have been conducted on the hepatotoxicity as well as 
general organ toxicity of these three anticancer drugs 
(9-10). These include light and electron microscopic 
studies of various organs and biochemical studies of 
liver enzymes (11-14). However, there is very limited 
information on the effects of these drugs on histopa-
thology and ultrastructure of liver cells. Further, a 
variety of agents including anti-oxidants have been 
shown to attenuate the hepatotoxicity of these three 
compounds (15-17). Also, analogues of these com-
pounds have been synthesized and shown to be much 
less toxic (18).  
In the present study, we investigated the effects 
of Cisplatin, doxorubicin and 5-FU belonging to dif-
ferent chemical classes on rat liver toxicity. We 
showed that the drugs induced drastic abnormalities 
with respect to body and liver weight changes as well 
as the histology and the ultrastructure of liver tissue. 
We further identified pathological features at both 
structural and ultrastructural levels, which could be 
used to adjust the dose and duration of treatment. 
Materials and methods 
Animals studies and drug treatment 
All of the procedures involving animals in this 
study were approved by the institution’s animal wel-
fare regulatory committee. Thirty five adult fertile 
inbred male albino rats were divided into seven 
groups (n=5). The first and second group of rats was 
treated  intraperitoneally with low (0.2mg/kg) or 
therapeutic (1mg/kg) doses of cisplatin, respectively. 
The third and the fourth group of rats were treated 
intraperitoneally with low (0.2mg/kg) therapeutic 
(1mg/kg) doses of doxorubicin alone, respectively. 
The fifth and sixth group of rats were treated intrap-
eritoneally with low (10mg/kg) or therapeutic 
(20mg/kg) doses of 5-FU alone, respectively. The re-
maining group of rats (n=5) received vehicle (PBS) 
alone. Body weights were measured twice weekly to 
determine weight changes during the course of 
treatment.   
Histological studies  
At the end of treatment both control and ex-
perimental rats were euthanized using carbon diox-
ide. The livers were collected from all the groups, 
fixed in 10% formalin in saline, dehydrated in as-
cending grades of ethyl alcohol, cleared in xylol and 
mounted in molten paraplast at 58-62ºC. Five micron 
sections were obtained, stained with Harris Hema-
toxylin & Eosin and evaluated for any structural 
changes under a bright field microscope. 
Electron microscopy analysis 
Liver tissue from both control and treated 
groups were immediately fixed in 2.5% glutaralde-
hyde and 2% paraformaldehyde in 0.1 M cacodylate 
buffer (pH 7.4). After rinsing in 0.1 M cacodylate 
buffer, samples were post fixed in a buffered solution 
of 1% osmium tetroxide at 4°C for 1.5 hour. This was 
followed by dehydration in ascending grades of ethyl 
alcohol (30%, 50%, 70%, 90%, and absolute) and em-
bedded in epoxy-resin. Ultrathin sections were ob-
tained with a diamond knife on a LKB microtome and 
mounted on formvar-coated grids, stained with 
uranyl acetate and lead citrate and evaluated for 
structural abnormalities with a Joel Transmission 
electron microscope.  
Statistical analysis 
Means and standard deviations were calculated 
from the five replicates per each group. Student’s 
t-test was performed and the differences were con-
sidered significant when P < 0.05.  
Results 
Body weight 
Body weights were measured twice weekly at 1, 
4, 8, 12, 16 and 20 days post-treatment. The results 
demonstrate that treatments with both low and 
therapeutic (Fig. 1) doses of cisplatin, doxorubicin and 
5-FU caused inhibition in the percentage of weight 
gain as compared to controls, indicating retardation in 
growth. 5-FU treatment exhibited the least adverse 
effects (Fig. 1). The results of low doses were quite 
similar to those of therapeutic treatment doses.  
Histological effects 
Light microscopic observation revealed that the 
control hepatic tissue showed normal large polygonal 
cells with prominent round nuclei and eosinophilic 
cytoplasm, and few spaced hepatic sinusoids ar-
ranged in-between the hepatic cords with fine ar-
rangement of Kupffer cells (Fig. 2A). In contrast, 
groups receiving cisplatin or doxorubicin at doses of 
0.2 mg/kg or 5-5-FU at 10mg/kg on alternate days for 
20 days showed massive hepatotoxicity, particularly 
with therapeutic doses. However, cisplatin and 
doxorubicin exhibited increased hepatotoxicity in 
comparison to 5-FU treatment. The most pronounced 
histopathological abnormalities observed in rats 
treated with 1mg/kg body weight involved dissolu-Int. J. Biol. Sci. 2009, 5 
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tion of hepatic cords, which appeared as empty vacu-
oles aligned by strands of necrotic hepatocytes (Fig. 
2B). The hepatic tissues showed the presence of dense 
focal inflammatory cells or necrotic tissues (Fig. 2C 
and 2D). Low dose-treatment of the drugs resulted in 
common histo-pathological alterations including 
perivascular round cell infiltration, associated with 
membrane changes of endothelial lining cells mani-
festing periportal fibrosis, marked degeneration of 
hepatic cords, increased incidence of vacuolar degen-
eration and apoptotic cell death (Fig. 2C-H). Doxoru-
bicin treatment showed higher tendency for liver fi-
brosis manifested by the presence of many spots of 
focal cellular granulomatous lesions (Figs. 2E and 2F). 
 
 
 
Figure 1. Chemotherapeutic treatment with cisplatin, doxorubicin and 5-FU influences the percentage of body weight gain 
in the rat. A: Percentages of body weight gain post treatment with low doses of cisplatin (0.2 mg/Kg), doxorubicin (0.2 
mg/Kg) and fluorouracil (10 mg/Kg). B: Percentages of body weight gain post treatment with either cisplatin (1 mg/Kg), 
doxorubicin (1 mg/Kg) and fluorouracil (20 mg/Kg). Body weights were measured twice weekly at 1, 4, 8, 12, 16 and 20 days 
post-treatment. Body weight gains during the course of the treatment of both control and experimental groups were 
determined. (*P < 0.05). Int. J. Biol. Sci. 2009, 5 
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Figure 2. Histopathological effects of cisplatin, doxorubicin and 5-FU in rat liver. A: Histology of normal control rat liver. 
B-D: Pronounced histopathological abnormalities seen in rats treated with cisplatin (1.0 mg/kg body weight). E-F: 
Doxorubicin-treated rat liver showing higher tendency for liver fibrosis manifested by the presence of many spots of focal 
collected cellular granulomatous lesions. G: Low dose treatment with 5-FU (10 mg/kg body weight) showed lower density 
of periportal inflammatory cells. H: Higher dose (20 mg/kg body weight) showed focal collection of inflammatory cells and 
loss of hepatic tissue structural pattern. CV, Central vein; BS, Blood sinusoids; DHC, Degenerated hepatic cord ; PF, Pe-
riportal fibrosis; FHN, focal hepatic necrosis; PPRCI, Periportal round cell infiltration; MBH, Massive breakdown hepato-
cytes; V, vacuole; RCI, round cell infiltration. Magnification: A&F, X400; B-E, X250, CX160. Int. J. Biol. Sci. 2009, 5 
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Control hepatocytes were normal polygonal 
with oval-shaped nuclei, cytoplasm crowded with 
organelles, particularly rough endoplasmic reticulum, 
smooth endoplasmic reticulum, golgi apparatus, ri-
bosomes, mitochondria and glycogen particles (Figs. 
3A and 3B). In contrast, the hepatocytes of liver from 
group treated with cisplatin showed pyknotic nuclei 
with irregular nuclear membrane, the cytoplasm 
contained vesiculated rough endoplasmic reticulum 
and atrophied mitochondria with ill-differentiated 
cisternae (Figs. 3C-F). The hepatic tissue showed nu-
merous spots of densely collected inflammatory cells 
composed mainly of macrophages and lymphocytes 
at the center and a number of fibrocytes at the pe-
riphery; the collagenous fibrils appeared markedly 
distributed in the necrotic foci (Figs. 3C-F). Doxorubi-
cin (Figs. 4A and 4B) and 5-FU (Figs. 4C and 4D) 
treatments revealed similar cytological alterations as 
in cisplatin treatment. 
 
 
 
Figure 3. Ultrastructural pathological effects of cisplatin in rat liver. A- B: Hepatic tissue of the control normal liver. C-F: 
Section of rat liver treated with cisplatin, showing dense collection of inflammatory cells including macrophages (M) and 
fibrocytes (F) forming pattern of cirrhotic liver (Lead citrate and uranyl acetate X 7500). The cytoplasm also contained 
vesiculated rough endoplasmic reticulum (VER) and atrophied mitochondria (Ma) with ill-differentiated cisternae.  Int. J. Biol. Sci. 2009, 5 
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Figure 4. Ultrastructural pathological effects of doxorubicin and 5-FU in rat liver. Doxorubicin (A-B) and 5-FU (C-D) 
treatments revealed similar cytological alterations as in cisplatin treatement (Lead citrate and uranyl acetate X 7500).  
 
 
Discussion 
  Although a number of studies have demon-
strated some side-effects of the chemotherapeutic 
drugs cisplatin, doxorubicin and 5-FU, the present 
study is the first comprehensive in vivo study reveal-
ing drastic abnormalities of these drugs both at cellu-
lar and ultrastructural levels. Rats treated with the 
anticancer drugs showed a significant decrease in 
body weight gain, suggesting that hepatotoxicity 
might have contributed to this loss as previously re-
ported (19). Dissection of these animals indicated that 
the loss of the body weights were due to loss of 
skeletal muscles and adipose tissue as previously 
suggested by Devlin et al (20). Moreover, the reduc-
tion in body weight of the animals in this study cor-
relate with the decreased food intake observed during 
the experimental period.  
  The present investigation showed many histo-
pathological and ultrastructural abnormalities in the 
liver including inflammatory infiltration, hyperplasia, 
periportal fibrosis, marked disruption of hepatic cords 
and dilated blood sinusoids. Many hepatocytes 
showed karyomegaly and pyknotic nuclei indicating 
apoptosis. The liver is known to accumulate signifi-
cant amounts of cisplatin, second only to the kidney 
(21), thus hepatotoxicity can be associated with cis-
platin treatment (22). Clinical evidence of cis-
platin-induced liver injury has been demonstrated by 
elevated activities of serum enzymes and bilirubin 
levels, and the development of jaundice (23). Cell 
death can result from naturally occurring apoptosis 
(physiological apoptosis) or from irreparable cell in-
jury (pathological apoptosis) as described by Farber 
(1994) (24). Apoptosis is a common feature of hepa-
totoxicity induced by many chemicals; it may precede 
necrosis, as in the hepatotoxicity induced by thio-
acetamide (25), or it may occur concurrently with ne-
crosis as in hepatotoxicity associated with aceta-
minophen (26). Cisplatin is thought to kill cells pri-
marily by forming DNA adducts, causing G2 arrest in 
the cell cycle, triggering apoptosis (27).  
  Doxorubicin is firmly established as a major 
therapeutic agent in the treatment of a wide variety of 
tumors. Although the precise mode of antitumor ac-
tion of this drug is not well established, it is thought to 
involve the interference with the synthesis of macro-
molecules, covalent DNA binding and DNA 
cross-linking, inhibition of topoisomerase II, arrest of 
tumor cell cycle progression in G2 phase, induction of Int. J. Biol. Sci. 2009, 5 
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apoptosis and generation of reactive oxygen radicals 
(28). Two of the listed phenomena require enzymatic 
activation, including covalent modification of mac-
romolecules and redox cycling with reactive oxygen 
species and both these effects can cause cytotoxicity 
(29). A number of studies indicate that enzyme acti-
vation of doxorubicin begins with the drug conver-
sion to a semiquinone free radical via one-electron 
reduction, and such a reaction is catalyzed by several 
enzymes, including P-450 reductase (30). In the pre-
sent study inflammatory cells forming granulomatous 
lesions and periportal fibrosis were detected after 
doxorubicin administration. Doxorubicin has been 
shown to induce accumulation of inflammatory cells 
(31), associated with increased activities of tissue 
aminotransferases, LDH and ALP, indicating hepatic 
damage (32).  
 5-fluorouracil has been used in the treatment of 
breast cancer, head and neck cancer, and gastrointes-
tinal cancers. When given intravenously, it is metabo-
lized in tissues to its active form, 
5-fluoro-deoxyuridine-monophosphate, which inhib-
its thymidylate synthase. The drug is also catabolized 
primarily in the liver, as dihydrouracil, and the re-
duced compound is then cleaved to 
α-fluoro-β-alanine, ammonia, urea, and carbon diox-
ide. Both the toxicity and antitumor effect are poten-
tiated if the catabolism is blocked by inhibiting dihy-
drouracil dehydrogenase. Although the liver plays a 
key role in its catabolism, 5-FU has not been reported 
to cause liver damage when given orally, and few 
reports have indicated its hepatotoxicity when given 
intravenously (33). Our study showed many histopa-
thological and ultrastructural abnormalities in the 
liver after intraperitoneal administration of 5-FU in-
cluding apoptotic cell death, appearance of numerous 
areas of inflammatory cells, and the cytoplasmic or-
ganelles were markedly affected with collagenous 
fibrils in a number of necrotic cells. 5-FU was found to 
produce liver toxicity associated with a number of 
abnormalities (34). 
In conclusion chemotherapeutic agents such as 
cisplatin, doxorubicin, and 5-FU cause direct hepatic 
toxicity. Appropriate protective measures must be 
applied with anticancer treatment for improving liver 
function. Our results provide in vivo evidence, at light 
microscopic and ultrastructural levels, of direct che-
motherapeutic hepatotoxicity caused by cisplatin, 
doxorubicin and 5-FU. Furthermore, this study iden-
tified pathological features at both structural and ul-
trastructural levels, which could be used as the basis 
for determining the appropriate dose of these drugs to 
reduce their hepatotoxic effects. 
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